Do we detect a new spectrum of biologically benign melanomas in the dermoscopy era?

References

• Ackerman AB. No one should die of malignant melanoma. J. Am. Acad. Dermatol.12, 115–116 (1985).
   PubMed Web of Science ®Google Scholar
• Zalaudek I, Ferrara G, Argenziano G, Ruocco V, Soyer HP. A practical guide on the diagnosis and treatment of cutaneous melanoma. Skin Med.2, 20–31 (2003).
   PubMedGoogle Scholar
• Ackerman AB. Disagreements with the current classification of malignant melanomas. Am. J. Surg. Pathol.6, 733–473 (1982).
   PubMedGoogle Scholar
• Ackerman AB, David KM. A unifying concept of malignant melanoma: biologic aspects. Hum. Pathol.17, 438–440 (1986).
   PubMedGoogle Scholar
• Swerlick RA, Chen S. The melanoma epidemic: more apparent than real? Mayo Clin. Proc.72, 559–564 (1997).
   PubMedGoogle Scholar
• Florez A, Cruces M. Melanoma epidemic: true or false? Int. J. Dermatol.43, 405–407 (2004).
   PubMed Web of Science ®Google Scholar
• Beddingfield FC III. The melanoma epidemic: res ipsa loquitur. Oncologist8, 459–465 (2003).
   PubMed Web of Science ®Google Scholar
• Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. Br. Med. J.331, 481 (2005).
   PubMed Web of Science ®Google Scholar
• Burton RC, Armstrong BK. Recent incidence trends imply a nonmetastasizing form of invasive melanoma. Melanoma Res.4, 107–113 (1994).
   PubMedGoogle Scholar
• Hiatt RA, Fireman B. The possible effect of increased surveillance on the incidence of malignant melanoma. Prev. Med.15, 652–660 (1986).
   PubMedGoogle Scholar
• Burton RC, Coates MS, Hersey P et al. An analysis of a melanoma epidemic. Int. J. Cancer55, 765–770 (1993).
   PubMed Web of Science ®Google Scholar
• Swerlick RA, Chen S. The melanoma epidemic. Is increased surveillance the solution or the problem? Arch. Dermatol.132, 881–884 (1996).
   PubMedGoogle Scholar
• Carlson JA, Slominski A, Linette GP et al. Malignant melanoma 2003: predisposition, diagnosis, prognosis, and staging. Am. J. Clin. Pathol.120(Suppl.), S101–S127 (2003).
   PubMedGoogle Scholar
• Argenziano G, Soyer HP. Dermoscopy of pigmented skin lesions – a valuable tool for early diagnosis of melanoma. Lancet Oncol.2, 443–449 (2001).
   PubMed Web of Science ®Google Scholar
• Soyer HP, Argenziano G, Talamini R, Chimenti S. Is dermoscopy useful for the diagnosis of melanoma? Arch. Dermatol.137, 1361–1363 (2001).
   PubMedGoogle Scholar
• Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch. Dermatol.137, 1343–1350 (2001).
   PubMedGoogle Scholar
• Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol.3, 159–165 (2002).
   PubMed Web of Science ®Google Scholar
• Binder M, Schwarz M, Winkler A et al. Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch. Dermatol.131, 286–291 (1995).
   PubMed Web of Science ®Google Scholar
• Argenziano G, Soyer HP, Chimenti S et al. Dermocopy of pigmented skin lesions: results of a consensus meeting via the Internet. J. Am. Acad. Dermatol.48, 679–693 (2003).
   PubMed Web of Science ®Google Scholar
• Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications oberserved in early melanoma, atypical nevi, and common nevi. J. Am. Acad. Dermatol.43, 467–746 (2000).
   PubMed Web of Science ®Google Scholar
• Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch. Dermatol.137, 1583–1589 (2001).
   PubMedGoogle Scholar
• Skvara H, Teban L, Fiebiger M, Binder M, Kittler H. Limitations of dermoscopy in the recognition of melanoma. Arch. Dermatol.141, 155–160 (2005).
   PubMedGoogle Scholar
• Kittler H, Binder M. Follow-up of melanocytic skin lesions with digital dermoscopy: risks and benefits. Arch. Dermatol.138, 1379 (2002).
   PubMedGoogle Scholar
• Kittler H, Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch. Dermatol.137, 1590–1595 (2001).
   PubMedGoogle Scholar
• Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch. Dermatol.141, 998–1006 (2005).
   PubMed Web of Science ®Google Scholar
• Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W. Long-term dermoscopic follow-up of melanocytic naevi: clinical outcome and patient compliance. Br. J. Dermatol.149, 79–86 (2003).
   PubMedGoogle Scholar
• Malvehy J, Puig S.Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin. Dermatol.20, 297–304 (2002).
   PubMed Web of Science ®Google Scholar
• Ferrara G, Zalaudek I, Di Stefani A, Soyer HP, Argenziano G. Do we detect a new spectrum of biologically “benign” melanomas in the dermoscopy era? Melanoma Res.14, 567–568 (2004).
   PubMed Web of Science ®Google Scholar
• Carli P, Massi D, De Giorgi V, Mannone F, Giannotti B. A 10-year-old in situ melanoma? Arch. Dermatol.138, 980–981 (2002).
   PubMedGoogle Scholar
• Daniotti M, Oggionni M, Ranzani T et al. BRAF alterations are associated with complex mutational profiles in malignant melanoma. Oncogene23, 5968–5977 (2004).
   PubMed Web of Science ®Google Scholar
• Balazs M, Adam Z, Treszl A, Begany A, Hunyadi J, Adany R. Chromosomal imbalances in primary and metastatic melanomas revealed by comparative genomic hybridization. Cytometry46, 222–232 (2001).
   PubMedGoogle Scholar
• Casorzo L, Luzzi C, Nardacchione A, Picciotto F, Pisacane A, Risio M. Fluorescence in situ hybridization (FISH) evaluation of chromosomes 6, 7, 9 and 10 throughout human melanocytic tumorigenesis. Melanoma Res.15, 155–160 (2005).
   PubMed Web of Science ®Google Scholar
• Treszl A, Ladanyi A, Rakosy Z, Buczko Z, Adany R, Balazs M. Molecular cytogenetic characterization of a novel cell line established from a superficial spreading melanoma. Front. Biosci.11, 1844–1853 (2006).
   PubMedGoogle Scholar
• Pellacani G, Cesinaro AM, Longo C, Grana C, Seidenari S. Microscopic in vivo description of cellular architecture of dermoscopic pigment network in nevi and melanomas. Arch. Dermatol.141, 147–154 (2005).
   PubMedGoogle Scholar
• Carlson JA. Tumor doubling time of cutaneous melanoma and its metastasis. Am. J. Dermatopathol.25(4), 291–299 (2003).
   PubMedGoogle Scholar
• Shaw H, Thompson J, McCarthy W. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer82(9), 1799–800 (1998).
   PubMedGoogle Scholar
• Tsao H, Cosimi AB, Sober AJ. Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer79(12), 2361–2370 (1997).
   PubMed Web of Science ®Google Scholar
• Gamel JW, George SL, Edwards MJ, Seigler HF. The long-term clinical course of patients with cutaneous melanoma. Cancer95(6), 1286–1293 (2002).
   PubMedGoogle Scholar
• Harman KE, Fuller LC, Salisbury JR, Higgins EM, du Vivier AW. Trends in the presentation of cutaneous malignant melanoma over three decades at King’s College Hospital, London. Clin. Exp. Dermatol.29(5), 563–566 (2004).
   PubMedGoogle Scholar
• Guitart J, Lowe L, Piepkorn M et al. Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch. Dermatol.138(5), 603–608 (2002).
   PubMedGoogle Scholar